Literature DB >> 16505102

A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

Christophe Marchand1, Smitha Antony, Kurt W Kohn, Mark Cushman, Alexandra Ioanoviciu, Bart L Staker, Alex B Burgin, Lance Stewart, Yves Pommier.   

Abstract

We show that five topoisomerase I inhibitors (two indenoisoquinolines, two camptothecins, and one indolocarbazole) each intercalate between the base pairs flanking the cleavage site generated during the topoisomerase I catalytic cycle and are further stabilized by a network of hydrogen bonds with topoisomerase I. The interfacial inhibition paradigm described for topoisomerase I inhibitors can be generalized to a variety of natural products that trap macromolecular complexes as they undergo catalytic conformational changes that create hotspots for drug binding. Stabilization of such conformational states results in uncompetitive inhibition and exemplifies the relevance of screening for ligands and drugs that stabilize ("trap") these macromolecular complexes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505102      PMCID: PMC2860177          DOI: 10.1158/1535-7163.MCT-05-0456

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  65 in total

1.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

2.  Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor.

Authors:  Louis Renault; Bernard Guibert; Jacqueline Cherfils
Journal:  Nature       Date:  2003-12-04       Impact factor: 49.962

3.  Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex.

Authors:  C R Kissinger; H E Parge; D R Knighton; C T Lewis; L A Pelletier; A Tempczyk; V J Kalish; K D Tucker; R E Showalter; E W Moomaw
Journal:  Nature       Date:  1995-12-07       Impact factor: 49.962

4.  Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.

Authors:  J Choi; J Chen; S L Schreiber; J Clardy
Journal:  Science       Date:  1996-07-12       Impact factor: 47.728

5.  DNA topoisomerase I is essential in Drosophila melanogaster.

Authors:  M P Lee; S D Brown; A Chen; T S Hsieh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

6.  Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin.

Authors:  Lei Jin; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-30       Impact factor: 11.205

7.  Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.

Authors:  G Kohlhagen; K D Paull; M Cushman; P Nagafuji; Y Pommier
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

8.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

9.  The domain organization of human topoisomerase I.

Authors:  L Stewart; G C Ireton; J J Champoux
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

10.  Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism.

Authors:  Elena Mossessova; Richard A Corpina; Jonathan Goldberg
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

View more
  34 in total

1.  Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Authors:  Dhriti Sooryakumar; Thomas S Dexheimer; Beverly A Teicher; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2011-06-02       Impact factor: 6.261

Review 2.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

3.  Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins.

Authors:  Kahina Oussedik; Jean-Christophe François; Ludovic Halby; Catherine Senamaud-Beaufort; Géraldine Toutirais; Sabrina Dallavalle; Yves Pommier; Claudio Pisano; Paola B Arimondo
Journal:  FASEB J       Date:  2010-02-23       Impact factor: 5.191

4.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.

Authors:  Keya Bandyopadhyay; Ruth A Gjerset
Journal:  Biochemistry       Date:  2011-01-12       Impact factor: 3.162

Review 5.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 6.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

7.  Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

Authors:  Maris A Cinelli; Brenda Cordero; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

8.  Development of purely structure-based pharmacophores for the topoisomerase I-DNA-ligand binding pocket.

Authors:  Malgorzata N Drwal; Keli Agama; Yves Pommier; Renate Griffith
Journal:  J Comput Aided Mol Des       Date:  2013-12-01       Impact factor: 3.686

9.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

Review 10.  Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy.

Authors:  Thomas S Dexheimer; Smitha Antony; Christophe Marchand; Yves Pommier
Journal:  Anticancer Agents Med Chem       Date:  2008-05       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.